BENITEC BIOPHARMA INC. (BNTC) Return on equity 2019–2024
BENITEC BIOPHARMA INC. (BNTC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-46.0%FY2024 · since FY2019: 15.7% → -46.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -46.0% | +9638.1 pp |
| FY2023 | -9684.2% | -9052.4 pp |
| FY2022 | -631.8% | -562.4 pp |
| FY2021 | -69.4% | +11.4 pp |
| FY2020 | -80.8% | -96.5 pp |
| FY2019 | 15.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More BNTC financial trends
BNTC RevenueBNTC Net incomeBNTC Net marginBNTC Gross profitBNTC Gross marginBNTC Operating incomeBNTC Operating marginBNTC Operating cash flowBNTC Free cash flowBNTC Capital expendituresBNTC Stock buybacksBNTC Dividends paidBNTC Total assetsBNTC Total liabilitiesBNTC Shareholders’ equityBNTC overview →